Travere Therapeutics Reports Strong Preliminary Q4/FY25 Sales, Healthy Cash, and Imminent FILSPARI FSGS PDUFA Date

summarizeZusammenfassung

Travere Therapeutics' preliminary financial results indicate robust commercial performance for FILSPARI in IgAN, with significant sales growth and a strong cash position. The most critical near-term catalyst is the imminent PDUFA target action date for FILSPARI in FSGS, which, if approved, would open a new, substantial market for the company's lead product. Additionally, the restart of the pivotal Phase 3 HARMONY Study for pegtibatinase signals progress in its pipeline for classical HCU, offering long-term growth potential. Investors should closely monitor the FDA's decision on FILSPARI for FSGS, as it represents a major value inflection point.

check_boxSchlusselereignisse

• Strong Preliminary Q4 and Full-Year 2025 Sales

  The company reported preliminary U.S. net product sales of approximately $127 million for Q4 2025 and $410 million for the full year 2025. FILSPARI sales for IgAN reached approximately $103 million in Q4 2025, representing 108% year-over-year growth.

• Healthy Cash Position

  Travere Therapeutics ended 2025 with approximately $323 million in cash, cash equivalents, and marketable securities, providing a solid financial runway.

• Imminent FILSPARI FSGS Regulatory Decision

  The PDUFA target action date for the sNDA seeking full approval for FILSPARI in Focal Segmental Glomerulosclerosis (FSGS) is January 13, 2026. The company has submitted responses to recent FDA information requests and is prepared for a commercial launch if approved.

• Pivotal Phase 3 HARMONY Study Restart

  The pivotal Phase 3 HARMONY Study of pegtibatinase for classical Homocystinuria (HCU) is on track to restart in the first quarter of 2026, following manufacturing process optimization.

auto_awesomeAnalyse

Travere Therapeutics' preliminary financial results indicate robust commercial performance for FILSPARI in IgAN, with significant sales growth and a strong cash position. The most critical near-term catalyst is the imminent PDUFA target action date for FILSPARI in FSGS, which, if approved, would open a new, substantial market for the company's lead product. Additionally, the restart of the pivotal Phase 3 HARMONY Study for pegtibatinase signals progress in its pipeline for classical HCU, offering long-term growth potential. Investors should closely monitor the FDA's decision on FILSPARI for FSGS, as it represents a major value inflection point.